Principal Financial Group
CHRS icon

Principal Financial Group’s Coherus Oncology CHRS Stock Holding History

Principal Financial Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,372
Closed -$30.1K – 2259
2024
Q2 		$30.1K Sell
17,372
-7,093
-29% -$14.3K ﹤0.01% 2320
2024
Q1 		$58.5K Sell
24,465
-93
-0.4% -$229 ﹤0.01% 2332
2023
Q4 		$81.8K Buy
24,558
+176
+0.7% +$471 ﹤0.01% 2291
2023
Q3 		$91.2K Sell
24,382
-369,858
-94% -$1.71M ﹤0.01% 2296
2023
Q2 		$1.68M Sell
394,240
-8,212
-2% -$48.5K ﹤0.01% 1782
2023
Q1 		$2.75M Sell
402,452
-9,135
-2% -$70.9K ﹤0.01% 1706
2022
Q4 		$3.26M Sell
411,587
-19,686
-5% -$151K ﹤0.01% 1666
2022
Q3 		$4.14M Sell
431,273
-39,532
-8% -$400K ﹤0.01% 1556
2022
Q2 		$3.41M Sell
470,805
-20,141
-4% -$175K ﹤0.01% 1681
2022
Q1 		$6.34M Sell
490,946
-28,666
-6% -$365K ﹤0.01% 1575
2021
Q4 		$8.29M Sell
519,612
-123,670
-19% -$2.16M 0.01% 1490
2021
Q3 		$10.3M Sell
643,282
-17,636
-3% -$259K 0.01% 1385
2021
Q2 		$9.14M Buy
660,918
+103,886
+19% +$1.47M 0.01% 1472
2021
Q1 		$8.14M Buy
557,032
+10,018
+2% +$170K 0.01% 1482
2020
Q4 		$9.51M Sell
547,014
-34,204
-6% -$609K 0.01% 1261
2020
Q3 		$10.7M Buy
581,218
+48,953
+9% +$911K 0.01% 1034
2020
Q2 		$9.51M Buy
532,265
+485,108
+1,029% +$8.21M 0.01% 1087
2020
Q1 		$765K Buy
47,157
+629
+1% +$11.6K ﹤0.01% 1783
2019
Q4 		$838K Buy
46,528
+35,710
+330% +$659K ﹤0.01% 1859
2019
Q3 		$219K Buy
10,818
+177
+2% +$3.54K ﹤0.01% 2122
2019
Q2 		$235K Sell
10,641
-7
-0.1% -$122 ﹤0.01% 2116
2019
Q1 		$145K Buy
+10,648
New +$142K ﹤0.01% 2142
2018
Q2 		– Sell
-10,410
Closed -$115K – 2277
2018
Q1 		$115K Buy
+10,410
New +$114K ﹤0.01% 2149
2017
Q3 		– Sell
-140,390
Closed -$2.02M – 2210
2017
Q2 		$2.02M Buy
140,390
+1,950
+1% +$37.5K ﹤0.01% 1740
2017
Q1 		$2.93M Buy
+138,440
New +$3.41M ﹤0.01% 1675

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Financial Group's CHRS Position: Q3 2024 in Review

Principal Financial Group sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 17,372 shares — an estimated $30.1K sold.

Principal Financial Group first reported a position in CHRS in Q1 2017 and held it in 25 quarters. The position peaked at $10.7M in Q3 2020. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Principal Financial Group reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 17,372 Coherus Oncology shares in Q3 2024, an estimated $30.1K.
  • Principal Financial Group first reported a position in Coherus Oncology in Q1 2017 and held it in 25 quarters.
  • Principal Financial Group's Coherus Oncology position peaked at $10.7M in Q3 2020.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.